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Abstract: Panic disorder is a chronic and disabling condition that is often accompanied by other 
psychiatric and medical conditions. The serotonin reuptake inhibitors (SSRIs) and serotonin-
norepinephrine reuptake inhibitors (SNRIs) have been used effectively with panic disorder (PD) 
and conditions in which panic attacks frequently occur. Escitalopram is the most selective SSRI 
and a variety of evidence suggests it is of great value in the treatment of panic disorder. In this 
paper, we review the theoretical and practical implications of its use.
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Introduction
Panic disorder is a common and frequently chronic illness that often co-occurs with 
other psychiatric and medical conditions. For example, the National Comorbidity Sur-
vey-Replication study reported a 2.7% 12-month, and a 4.7% lifetime, prevalence (Kes-
sler, Berglund et al 2005; Kessler, Chiu et al 2005). Panic disorder often accompanies 
general medical as well as psychiatric conditions (Simon and Fischmann 2005). Patients 
with panic disorder are at an increased risk for suicide (Goodwin and Roy-Byrne 2006), 
which appears to increase with comorbid depression (Black 1995). Panic disorder is 
also associated with autonomic instability, also worsened when depression is present 
(Townsend 1998).
Much evidence suggests that the selective serotonin uptake inhibitor (SSRI) 
escitalopram is effective in the treatment of panic disorder (PD). The tricyclic 
antidepressants (TCAs) and MAO inhibitors (MAOIs) are also effective in this 
population (Garakoni et al 1984). However, TCAs are associated with potentially fatal 
arrhythmias, either in monotherapy or in combination with ﬂ  uoxetine (Witchel et al) 
and MAO inhibitors must be used with caution in many populations (Yamada and 
Yasuhara 2004). In this review, we consider neurobiological evidence that supports 
the use of escitalopram in PD and the clinical trials that have been performed with 
escitalopram in the treatment of anxiety.
Neurobiological considerations
While numerous interacting neuroanatomical sites have been implicated in the 
pathogenesis of PD, a dysfunction of the serotonin (5-HT) system appears to play a 
crucial role in development and perpetuation of panic attacks (Grove 1997; Maron 
2006). The selective SSRIs and the serotonin-norepinephrine reuptake inhibitors 
(SNRIs) have demonstrated efﬁ  cacy in the treatment of panic disorder, as well as 
conditions frequently comorbid with it, including major depression, generalized 
anxiety disorder, post-traumatic stress disorder, social anxiety disorder and obsessive-
compulsive disorder (Pollack 2005). SSRIs and SNRIs, in contrast with tricyclic anti-
depressants, monoamine oxidase inhibitors and benzodiazepines, hold more favorable 
side effect proﬁ  les and a lower likelihood of drug interaction (Lader 2005).Neuropsychiatric Disease and Treatment 2007:3(6) 836
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Research into the mechanisms underlying fear and 
avoidance has implicated the serotonergic and noradrenergic 
systems in speciﬁ  c locations (Goddard 1997; Grove 1997; 
Gorman 2000; Ninan 2005). Several models integrate the 
panic response through the amygdala, with projections to the 
hypothalamus, locus ceruleus, periaqueductal gray region, 
parabrachial nucleus and thalamus (Gorman 2000). While the 
role of 5-HT in panic disorder is clearly important, research-
ers report conﬂ  icting evidence about whether the condition 
represents a state of 5-HT deﬁ  ciency or excess (Maron 2006). 
Serotonin has an inhibitory effect within three brain systems: 
the noradrenergic activity of the locus ceruleus, the defense 
and escape behaviors mediated by the periaqueductal gray 
region, and the production of corticotrophin releasing factor 
(CRF) by the hypothalamus. SSRIs can produce an anti-panic 
activity through these mechanisms over time by reducing the 
“downstream manifestations of panic” (Gorman 2000).
Furthermore, the 5-HT1A auto-receptor is believed to 
play a role in counteracting the acute increase of serotonin 
after SSRI initiation, and it may be implicated in an elevated 
perception of somatic anxiety (Ceglia 2004; Sullivan 2005). 
Further research is needed to determine if escitalopram, 
highly potent at serotonin reuptake inhibition, is capable 
of producing a clinically signiﬁ  cant anxiolytic effect more 
rapidly than other agents in the SRRI class.
Clinical trials with citalopram 
in panic disorder
Although research into escitalopram as treatment for panic 
disorder per se has been relatively sparse, it has been shown 
to be effective in a number of anxiety disorders. Furthermore, 
escitalopram is the S-enantiomer of citalopram, a compound 
that is FDA-approved only for major depression, but which has 
demonstrated efﬁ  cacy in panic disorder in several controlled 
trials (Wade et al 1997; Lepola et al 1998; Perna et al 2001).
In the 1997 Wade trial, for example, a large sample of 
PD subjects were randomized to placebo, citalopram, and 
the tertiary tricyclic clomipramine, the latter itself effective 
for PD (Cassano et al 1988). Subjects were followed for 8 
weeks, and those given clomipramine at 60 or 90 mg/day and 
citalopram at doses between 20 to 60 mg/day had fewer panic 
attacks than on placebo. Interestingly, and perhaps suggestive 
of a negative effect of the R-enantiomer, citalopram at lower 
doses at end-of-trial had fewer panic attacks than the higher-
dosed subjects. Some have suggested that the presence 
of the R-enantiomer reduces the efﬁ  cacy of citalopram, 
whose anxiolytic and antidepressant effects are the result of 
escitalopram (Sanchez et al 2003).
Escitalopram itself is effective in generalized anxiety 
disorder (Davidson 2004; Baldwin and Nair 2005), which 
is frequently comorbid with panic disorder and in which 
panic attacks often occur. Social anxiety disorder is often 
accompanied by situational panic attacks, and escitalopram 
has been demonstrated to reduce social phobia symptoms 
(Lader et al 2004). In addition, studies of escitalopram in 
depression have shown a reduction in concurrent anxiety 
(Burke et al 2002; Olie et al 2006).
Clinical trials with escitalopram 
in panic disorder
The literature contains three studies of varying rigor and intent 
that examine escitalopram in primary panic disorder (Stahl 
et al 2003; Sayer and Cetin 2004; Rampello et al 2006). The 
small, open-label Sayer and Cetin trial found escitalopram 
useful, but was presented as a poster and available only as an 
abstract. Both the Stahl and Rampello studies were designed 
to discriminate clinical outcome in PD patients taking either 
citalopram or escitalopram. In animal models, R-citalopram 
has appeared to counteract the antidepressant effect of 
escitalopram (Mansari et al 2007), thus the hypothesis that 
citalopram may be less effective than its S-enantiomer.
The Stahl study was a randomized, double-blind, 
placebo-controlled, 10-week trial with 366 adults with PD. 
Patients were randomized to escitalopram at 10 to 20 mg 
daily; citalopram, 20 to 40 mg daily; or placebo. While 
citalopram and escitalopram were more effective than pla-
cebo in reducing both anticipatory anxiety and the frequency 
and intensity of panic attacks, escitalopram subjects sepa-
rated from placebo on one measure earlier than those taking 
citalopram. On the Panic and Agoraphobia scale, escitalo-
pram showed signiﬁ  cant improvement relative to placebo 
from week four onwards, whereas citalopram results did not 
obtain signiﬁ  cance until week eight.
Although the Rampello study also attempted to show the 
superiority of escitalopram, it had fewer, older subjects than 
Stahl’s and followed an open-label, naturalistic design. Forty 
men and women age 65 and older with panic disorder were 
assigned to either 10 mg escitalopram or 20 mg citalopram 
each day for 8 weeks. Although panic attack frequency 
was equivalently reduced in both groups, the escitalopram 
group showed fewer panic attacks at week 2, while the 
citalopram group separated from baseline panic attack num-
bers at week 4. The open-label nature of the Rampello trial 
hinders generalization of its results, however it does serve 
to underscore the effectiveness of both escitalopram and 
citalopram in this population.Neuropsychiatric Disease and Treatment 2007:3(6) 837
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Safety and tolerability
Stahl conﬁ  rmed the generally benign adverse event and 
safety proﬁ  le of escitalopram demonstrated in depression 
trials (Hirschfeld 2004). The rate of discontinuation due 
to adverse events for escitalopram was 6.3% compared to 
7.6% for placebo. Most treatment-emergency adverse events 
reported with escitalopram in major depression (Lexapro 
[package insert] 2007) are common to other SRIs. Sexual 
side effects, such as delayed ejaculation and anogasmia, 
and gastrointestinal symptoms, including nausea and 
diarrhea, have been ascribed to SRI agonism at the 5-HT2 
and 5-HT3 receptors, respectively (Stahl 1998). As with all 
SRIs, clinicians must be alert to the possibility of iatrogenic 
mania (Goldbert and Truman 2003), as well as suicidal ide-
ation or behavior, especially at treatment initiation (Bridge 
et al 2007).
Conclusion
Many lines of evidence predict that a highly selective 
SSRI like escitalopram would be effective in PD, and 
several clinical trials with other anxiety disorders and in 
“anxious” depression support its ﬁ  rst-line use. As PD often 
presents concurrently with other anxiety disorders and 
major depression, escitalopram has the potential to reduce 
numerous related symptoms. Its favorable tolerability 
predicts successful initiation and maintenance of treatment 
in PD, and its safety proﬁ  le supports its use in individuals 
with concomitant general medical conditions.
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